Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioSite Triage Becomes The First BNP Test To Receive A CLIA Waiver

This article was originally published in The Gray Sheet

Executive Summary

BioSite plans to market its Triage BNP test to the 55,000 physician practices that most often treat heart failure patients after becoming the first BNP test manufacturer to receive a CLIA waiver from FDA

You may also be interested in...



Beckman Coulter Buys Cardiac Test Developer Biosite For $1.55 Billion

In a $1.55 billion acquisition plan announced March 25, Beckman Coulter looks to combine its strength as a leading manufacturer of lab instruments with the complementary expertise of diagnostic test developer Biosite

Beckman Coulter Buys Cardiac Test Developer Biosite For $1.55 Billion

In a $1.55 billion acquisition plan announced March 25, Beckman Coulter looks to combine its strength as a leading manufacturer of lab instruments with the complementary expertise of diagnostic test developer Biosite

People In Brief

Shakeup at FoxHollow: Ron Steckel replaces David Martin as COO, and Richard Zimmer replaces Bill Hoffman as VP-sales. Steckel moves up from senior VP-operations and research & development, where he focused on improving operating efficiency. Zimmer has spent two years with FoxHollow, serving as director of sales since October. The firm recently announced plans for new studies of its SilverHawk plaque excision system (1"The Gray Sheet" Jan. 16, 2006, p. 7). However, FoxHollow's stock has dropped 38.5% from $45.46 on Dec. 12, when the firm announced the resignation of CEO Robert Thomas, to close Feb. 10 at $27.95 (2"The Gray Sheet" Jan. 9, 2006, p. 13)...

Related Content

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel